123 related articles for article (PubMed ID: 33838299)
1. Association of HLA mismatch and MTOR inhibitor regimens with malignancy and mortality after kidney transplantation.
Santos AH; Chen C; Leghrouz MA; Bueno EP; Lee JJ; Wen X
Transpl Immunol; 2021 Jun; 66():101391. PubMed ID: 33838299
[TBL] [Abstract][Full Text] [Related]
2. Role of standard HLA mismatch in modifying associations between non-pharmacologic risk factors and solid organ malignancy after kidney transplantation.
Santos AH; Mehta R; Ibrahim H; Leghrouz MA; Alquadan K; Belal A; Lee JJ; Wen X
Transpl Immunol; 2023 Oct; 80():101885. PubMed ID: 37414265
[TBL] [Abstract][Full Text] [Related]
3. Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant.
Gao Y; Twigg AR; Hirose R; Roll GR; Nowacki AS; Maytin EV; Vidimos AT; Rajalingam R; Arron ST
JAMA Dermatol; 2019 Mar; 155(3):307-314. PubMed ID: 30673077
[TBL] [Abstract][Full Text] [Related]
4. Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review.
Olszewska B; Imko-Walczuk B; Dębska-Ślizień A
Postepy Dermatol Alergol; 2023 Apr; 40(2):187-193. PubMed ID: 37312910
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation.
Isakova T; Xie H; Messinger S; Cortazar F; Scialla JJ; Guerra G; Contreras G; Roth D; Burke GW; Molnar MZ; Mucsi I; Wolf M
Am J Transplant; 2013 Jan; 13(1):100-10. PubMed ID: 23025566
[TBL] [Abstract][Full Text] [Related]
6. mTOR Inhibitors Prevent CMV Infection through the Restoration of Functional αβ and γδ T cells in Kidney Transplantation.
Kaminski H; Marseres G; Yared N; Nokin MJ; Pitard V; Zouine A; Garrigue I; Loizon S; Capone M; Gauthereau X; Mamani-Matsuda M; Coueron R; Durán RV; Pinson B; Pellegrin I; Thiébaut R; Couzi L; Merville P; Déchanet-Merville J
J Am Soc Nephrol; 2022 Jan; 33(1):121-137. PubMed ID: 34725108
[TBL] [Abstract][Full Text] [Related]
7. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
Opelz G; Unterrainer C; Süsal C; Döhler B
Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
[TBL] [Abstract][Full Text] [Related]
9. Timing of mTORI usage and outcomes in kidney transplant recipients.
Lim LM; Kung LF; Kuo MC; Huang AM; Kuo HT
Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978
[TBL] [Abstract][Full Text] [Related]
10. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
[TBL] [Abstract][Full Text] [Related]
11. Induction Type and Outcomes in HLA-DR Mismatch Kidney Transplantation.
Sureshkumar KK; Chopra B
Transplant Proc; 2019; 51(6):1796-1800. PubMed ID: 31399165
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients.
Gluck M; Hodak E; Davidovici B
Dermatol Ther; 2022 Aug; 35(8):e15649. PubMed ID: 35716099
[TBL] [Abstract][Full Text] [Related]
13. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
[TBL] [Abstract][Full Text] [Related]
14. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
[No Abstract] [Full Text] [Related]
15. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
[TBL] [Abstract][Full Text] [Related]
16. What is the impact of human leukocyte antigen mismatching on graft survival and mortality in renal transplantation? A meta-analysis of 23 cohort studies involving 486,608 recipients.
Shi X; Lv J; Han W; Zhong X; Xie X; Su B; Ding J
BMC Nephrol; 2018 May; 19(1):116. PubMed ID: 29776389
[TBL] [Abstract][Full Text] [Related]
17. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S
Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574
[TBL] [Abstract][Full Text] [Related]
18. Human leukocyte antigen type as a risk factor for nonmelanomatous skin cancer in patients after renal transplantation.
Bock A; Bliss RL; Matas A; Little JA
Transplantation; 2004 Sep; 78(5):775-8. PubMed ID: 15371688
[TBL] [Abstract][Full Text] [Related]
19. Association Between HLA Type and Skin Cancer in Kidney Transplant Recipients.
Cegielska A; Dębska-Ślizień A; Moszkowska G; Imko-Walczuk B; Rutkowski B
Transplant Proc; 2016 Jun; 48(5):1608-10. PubMed ID: 27496455
[TBL] [Abstract][Full Text] [Related]
20. The role of new immunosuppressive drugs in nonmelanoma skin cancer in renal transplant recipients.
Bernat-García J; Morales Suárez-Varela M; Vilata-Corell JJ; Marquina-Vila A; Pallardo L; Crespo J
Actas Dermosifiliogr; 2014 Dec; 105(10):940-6. PubMed ID: 25062648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
